Hutchison China MediTech Limited Share Price London S.E.
Equities
KYG4672N1198
Pharmaceuticals
Sales 2024 * | 681M 0 54.55B | Sales 2025 * | 836M 0 66.91B | Capitalization | 3.08B 0 247B |
---|---|---|---|---|---|
Net income 2024 * | -109M - -8.73B | Net income 2025 * | -6M - -480M | EV / Sales 2024 * | 4.23 x |
Net cash position 2024 * | 199M 0 15.89B | Net cash position 2025 * | 306M 0 24.47B | EV / Sales 2025 * | 3.32 x |
P/E ratio 2024 * |
-26.7
x | P/E ratio 2025 * |
561
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
Latest transcript on Hutchison China MediTech Limited
Managers | Title | Age | Since |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 31/12/04 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 30/06/08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 31/12/99 |
Graeme Jack
BRD | Director/Board Member | 73 | 28/02/17 |
Dan Eldar
BRD | Director/Board Member | 70 | 31/07/16 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |